Background Whether inhaled corticosteroids (ICSs) reduce major adverse cardiovascular events (MACEs) in people with chronic obstructive pulmonary disease (COPD) is debated. Objectives To establish, ...

Joan B. Soriano, MD, PhD; Don D. Sin, MD, FCCP; Xuekui Zhang, MSc; Pat G. Camp, MSc; Julie A. Anderson, MD; Nick R. Anthonisen, MD; A. Sonia Buist, MD; P. Sherwood ...

Please provide your email address to receive an email when new articles are posted on . This analysis spanned from 2016 to 2022. Nearly 50% of patients were initially prescribed LABA/inhaled ...

uea.ac.uk Background The effect of inhaled corticosteroids (ICS) on fracture risk in patients with chronic obstructive pulmonary disease (COPD) remains uncertain. The aim of this study was to evaluate ...

Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

is more effective in reducing the annual rate of exacerbations compared with LABA-LAMA or LABA-inhaled corticosteroid in patients with chronic obstructive pulmonary disease (COPD), a history of ...

Objective: To review the basis for the estimated comparative daily dosages of inhaled corticosteroids for children and adults that are presented in the National Heart, Lung, and Blood Institute's ...

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first ...

"Today's results are significant as they show for the first time the positive effect of directly switching to Ultibro Breezhaler from other COPD treatments, such as inhaled steroid-containing ...